- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.08. | NYRADA INC.: Change in substantial holding - M Azzi | 1 | ASX | ||
| NYRADA INC Aktie jetzt für 0€ handeln | |||||
| 05.08. | NYRADA INC.: CSANZ26 Conference Poster | 1 | ASX | ||
| 27.07. | NYRADA INC.: Quarterly Activities Report and Appendix 4C | - | ASX | ||
| 15.07. | NYRADA INC.: Response to ASX Price Query | - | ASX | ||
| 15.07. | NYRADA INC.: Change in substantial holding - M Azzi | - | ASX | ||
| 06.07. | NYRADA INC.: PROTECT-MI Phase IIa Clinical Trial Update No 2 | - | ASX | ||
| 30.06. | NYRADA INC.: Notification of cessation of securities - NYR | - | ASX | ||
| 30.06. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 30.06. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 29.06. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 29.06. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 16.06. | NYRADA INC.: Cleansing Statement | - | ASX | ||
| 16.06. | NYRADA INC.: Application for quotation of securities - NYR | - | ASX | ||
| 16.06. | NYRADA INC.: Change of Director's Interest Notice - JB | - | ASX | ||
| 16.06. | NYRADA INC.: PROTECT-MI Phase IIa Clinical Trial Update | - | ASX | ||
| 12.06. | Buy, hold, sell: Nick Scali, Nyrada, Wesfarmers shares | 3 | The Motley Fool Australia | ||
| 04.06. | NYRADA INC.: Investor Presentation | - | ASX | ||
| 03.06. | NYRADA INC.: Nyrada Successfully Completes Cardioprotection Pilot Study | - | ASX | ||
| 29.05. | NYRADA INC.: Nyrada Receives A$2.455M R&D Tax Incentive Rebate | - | ASX | ||
| 25.05. | NYRADA INC.: Cleansing Statement | - | ASX |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERA THERAPEUTICS | 31,630 | 0,00 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| SUMMIT THERAPEUTICS | 13,350 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| QIAGEN | 37,290 | -0,98 % | Qiagen überzeugt mit Zahlen, Micron ohne neuen Ausbruch und AST SpaceMobile verfehlt die Erwartungen - BÖRSE TO GO | Ein wenig wurde an den Börsen auch zu Beginn der neuen Woche noch aufgrund nachlassender Zinssorgen aufgeatmet. Begleitet wurde dies allerdings von eher unschönen Neuigkeiten aus Nahost, welche prompt... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,56 | +0,01 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| ERASCA | 18,390 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 367,40 | +0,16 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 21,625 | -0,02 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,610 | +0,04 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,950 | +0,05 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| KYMERA THERAPEUTICS | 117,37 | 0,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| CLIMB BIO | 16,340 | +0,06 % | Climb Bio, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 75,10 | +0,09 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,690 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,195 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,69 | -0,08 % | Kiniksa auf Wachstumskurs: ARCALYST-Umsatz steigt, Pipeline wird ausgebaut |
NYRADA INC CDIS gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NYRADA INC CDIS finden Sie auf Wallstreet Online.